ALK Alkemy Capital Investments Plc

 
TIDMALK TIDMB 
 

On Wednesday, 15 November 2023 ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its nine-month interim report (Q3) 2023.

ALK will host a meeting for analysts and institutional investors that day at 1.30pm (CET) at which Management will review the financial results, the outlook and answer questions.

The meeting will be audio cast live on our website https://ir.alk.net, where the related presentation will be available shortly before the meeting begins.

To register for the conference call, please use this link https://dpregister.com/sreg/10183783/fad25cbd21 and follow the instructions. You will receive an email from diamondpass@choruscall.com with dial-in details, including a passcode and a pin code. Please make sure to whitelist diamondpass@choruscall.com https://www.globenewswire.com/Tracker?data=GNrZbo7xgxj8sOdfiEN3ojhmq8TVGaHk-M5da0bIawXPKNaG4ZUo8eg3vSKu2_qgFqFiNeM08CE27YiFjFRbVX0YWdnfwIS9JsfPj3A9nfOe4o0Axg3CS9Jb2FpM5igf and/or check your spam filter. We advise you to register on the day before the call at the latest.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Maiken Riise Andersen, tel. +45 5054 1434

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,700 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Attachment

   -- InvestorNews_09Nov23 
      https://ml-eu.globenewswire.com/Resource/Download/6fd2d8ff-9526-4a17-afa0-5c5da5a78170 
 
 
 

(END) Dow Jones Newswires

November 09, 2023 07:46 ET (12:46 GMT)

Alkemy Capital Investments (LSE:ALK)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024

Alkemy Capital Investments (LSE:ALK)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024